At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHAT Phathom Pharmaceuticals
Closed 05-15 16:00:00 EDT
11.87
-1.18
-9.04%
盘后11.94
+0.07+0.56%
18:44 EDT
High12.97Low11.86Vol1.11M
Open12.81D1 Closing13.05Amplitude8.51%
Mkt Cap942.84MTradable Cap683.32MTotal Shares79.43M
T/O13.45MT/O Rate1.93%Tradable Shares57.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Phathom (PHAT) Is Up 9.4% After Reaffirming 2026 Profitability Timeline And Narrowing Q1 Loss
Simply Wall St.  ·  05-09
Phathom (PHAT) Is Up 9.4% After Reaffirming 2026 Profitability Timeline And Narrowing Q1 Loss
Phathom to highlight VOQUEZNA at DDW annual meeting
Reuters  ·  05-01
Phathom to highlight VOQUEZNA at DDW annual meeting
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)
TIPRANKS  ·  05-01
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call
TIPRANKS  ·  05-01
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call
Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate
Benzinga  ·  04-30
Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate
BRIEF-Phathom Pharmaceuticals Q1 Net Income USD -30.369 Million
Reuters  ·  04-30
BRIEF-Phathom Pharmaceuticals Q1 Net Income USD -30.369 Million
Phathom Pharmaceuticals Q1 Adjusted EPS USD -0.18 VS. Ibes Estimate USD -0.32
THOMSON REUTERS  ·  04-30
Phathom Pharmaceuticals Q1 Adjusted EPS USD -0.18 VS. Ibes Estimate USD -0.32
Phathom Pharmaceuticals Inc - Maintains FY2026 Guidance; Expects Operating Profitability Beginning Q3 2026
THOMSON REUTERS  ·  04-30
Phathom Pharmaceuticals Inc - Maintains FY2026 Guidance; Expects Operating Profitability Beginning Q3 2026
Phathom Pharmaceuticals Q1 Revenue USD 58.301 Million VS. Ibes Estimate USD 57 Million
THOMSON REUTERS  ·  04-30
Phathom Pharmaceuticals Q1 Revenue USD 58.301 Million VS. Ibes Estimate USD 57 Million
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire  ·  04-30
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Pfizer (PFE) and Guardant Health (GH)
TIPRANKS  ·  04-28
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Pfizer (PFE) and Guardant Health (GH)
Phathom Pharmaceuticals to report first-quarter results, host webcast and conference call
Reuters  ·  04-20
Phathom Pharmaceuticals to report first-quarter results, host webcast and conference call
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
GlobeNewswire  ·  04-20
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
A Look At Phathom Pharmaceuticals (PHAT) Valuation After Recent Stock Momentum Shift
Simply Wall St.  ·  04-15
A Look At Phathom Pharmaceuticals (PHAT) Valuation After Recent Stock Momentum Shift
Phathom Pharmaceuticals announces annual shareholder meeting via webcast
Reuters  ·  04-07
Phathom Pharmaceuticals announces annual shareholder meeting via webcast
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  04-06
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Reuters  ·  03-27
BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Phathom Pharmaceuticals Raised to Overweight From Equal-Weight by Barclays
Dow Jones  ·  03-27
Phathom Pharmaceuticals Raised to Overweight From Equal-Weight by Barclays
BUZZ- Barclays raises Phathom Pharmaceuticals to 'overweight'; shares rise
Reuters  ·  03-27
BUZZ- Barclays raises Phathom Pharmaceuticals to 'overweight'; shares rise
Phathom Pharmaceuticals Inc. : Barclays Raises Target Price to $18 From $16
THOMSON REUTERS  ·  03-27
Phathom Pharmaceuticals Inc. : Barclays Raises Target Price to $18 From $16

Introduction

Company Name.
Phathom Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Issue price:
--